OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
Soo Yeon Baek, Woo Chul Noh, Sei‐Hyun Ahn, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 31, pp. 4864-4871
Closed Access | Times Cited: 28
Soo Yeon Baek, Woo Chul Noh, Sei‐Hyun Ahn, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 31, pp. 4864-4871
Closed Access | Times Cited: 28
Showing 1-25 of 28 citing articles:
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy
Lu-Qi Cao, Haidong Sun, Yuhao Xie, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Lu-Qi Cao, Haidong Sun, Yuhao Xie, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists
Jinna Lin, Shuqi Zheng, Qiang Liu
Cancer Treatment Reviews (2025) Vol. 133, pp. 102879-102879
Closed Access | Times Cited: 1
Jinna Lin, Shuqi Zheng, Qiang Liu
Cancer Treatment Reviews (2025) Vol. 133, pp. 102879-102879
Closed Access | Times Cited: 1
Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
Tamer Al-Batsh, Nayef Abdel-Razeq, Yosra Al-Masri, et al.
Biologics (2025) Vol. Volume 19, pp. 97-111
Open Access | Times Cited: 1
Tamer Al-Batsh, Nayef Abdel-Razeq, Yosra Al-Masri, et al.
Biologics (2025) Vol. Volume 19, pp. 97-111
Open Access | Times Cited: 1
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer
Kelly McCann, Shari Goldfarb, Tiffany A. Traina, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Kelly McCann, Shari Goldfarb, Tiffany A. Traina, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 7
Ovarian Suppression: Early Menopause and Late Effects
Chiara Molinelli, Flavia Jacobs, Guilherme Nader Marta, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 4, pp. 523-542
Open Access | Times Cited: 5
Chiara Molinelli, Flavia Jacobs, Guilherme Nader Marta, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 4, pp. 523-542
Open Access | Times Cited: 5
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer
Erika Hamilton, S. Loibl, Thomas Bachelot, et al.
Future Oncology (2025), pp. 1-12
Open Access
Erika Hamilton, S. Loibl, Thomas Bachelot, et al.
Future Oncology (2025), pp. 1-12
Open Access
Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics
Bandari BharathwajChetty, Anjana Sajeev, Ravichandran Vishwa, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 321-362
Closed Access | Times Cited: 4
Bandari BharathwajChetty, Anjana Sajeev, Ravichandran Vishwa, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 321-362
Closed Access | Times Cited: 4
Contemporary Review of the Management and Treatment of Young Breast Cancer Patients
Brooke Vuong, Ana I Jacinto, Sharon B. Chang, et al.
Clinical Breast Cancer (2024)
Closed Access | Times Cited: 4
Brooke Vuong, Ana I Jacinto, Sharon B. Chang, et al.
Clinical Breast Cancer (2024)
Closed Access | Times Cited: 4
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis
Andri Papakonstantinou, Guillermo Villacampa, Vı́ctor Navarro, et al.
EClinicalMedicine (2025) Vol. 81, pp. 103116-103116
Open Access
Andri Papakonstantinou, Guillermo Villacampa, Vı́ctor Navarro, et al.
EClinicalMedicine (2025) Vol. 81, pp. 103116-103116
Open Access
Efficacy of goserelin in ovarian function suppression and preservation for pre- and perimenopausal breast cancer patients: a systematic review
Nan Chen, Daniella Audi Blotta, Hee Jeong Kim, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Nan Chen, Daniella Audi Blotta, Hee Jeong Kim, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue
Xiaoshuan Liang, Yiwei Qin, Pengwei Li, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Xiaoshuan Liang, Yiwei Qin, Pengwei Li, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Clinical treatment score post-5 years and survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age
Jee Hyun Ahn, Suk Jun Lee, Seung Hye Yang, et al.
Breast Cancer Research and Treatment (2025)
Open Access
Jee Hyun Ahn, Suk Jun Lee, Seung Hye Yang, et al.
Breast Cancer Research and Treatment (2025)
Open Access
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes
Linxiaoxi Ma, Benlong Yang, Jiong Wu
Cancer Treatment Reviews (2024) Vol. 129, pp. 102770-102770
Open Access | Times Cited: 3
Linxiaoxi Ma, Benlong Yang, Jiong Wu
Cancer Treatment Reviews (2024) Vol. 129, pp. 102770-102770
Open Access | Times Cited: 3
Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR +/HER2 + early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up
Jie Ju, Songlin Gao, Jiayu Wang, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 6, pp. 439-447
Open Access | Times Cited: 2
Jie Ju, Songlin Gao, Jiayu Wang, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 6, pp. 439-447
Open Access | Times Cited: 2
Tata Memorial Centre Evidence Based Management of Breast cancer
Tabassum Wadasadawala, Shalaka Joshi, Sushmita Rath, et al.
Indian Journal of Cancer (2024) Vol. 61, Iss. Suppl 1, pp. S52-S79
Open Access | Times Cited: 2
Tabassum Wadasadawala, Shalaka Joshi, Sushmita Rath, et al.
Indian Journal of Cancer (2024) Vol. 61, Iss. Suppl 1, pp. S52-S79
Open Access | Times Cited: 2
Hormone receptor-positive early breast cancer in young women: A comprehensive review
Benjamín Walbaum, Isabel Garcia‐Fructuoso, Olga Martínez‐Sáez, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102804-102804
Closed Access | Times Cited: 2
Benjamín Walbaum, Isabel Garcia‐Fructuoso, Olga Martínez‐Sáez, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102804-102804
Closed Access | Times Cited: 2
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
Ruth O’Regan, Yi Zhang, Gini F. Fleming, et al.
JAMA Oncology (2024) Vol. 10, Iss. 10, pp. 1379-1379
Closed Access | Times Cited: 2
Ruth O’Regan, Yi Zhang, Gini F. Fleming, et al.
JAMA Oncology (2024) Vol. 10, Iss. 10, pp. 1379-1379
Closed Access | Times Cited: 2
Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics
Yuxuan Song, Shuang Ren, Xingmei Chen, et al.
Cancer Letters (2024) Vol. 590, pp. 216847-216847
Closed Access | Times Cited: 1
Yuxuan Song, Shuang Ren, Xingmei Chen, et al.
Cancer Letters (2024) Vol. 590, pp. 216847-216847
Closed Access | Times Cited: 1
Systemic Therapy in Breast Cancer
Chiara Corti, Hemali Batra-Sharma, Max F. Kelsten, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
Chiara Corti, Hemali Batra-Sharma, Max F. Kelsten, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer
Hunan Ye, Guang Lin, Xiaojia Wang
Translational Breast Cancer Research (2024) Vol. 5, pp. 20-20
Open Access | Times Cited: 1
Hunan Ye, Guang Lin, Xiaojia Wang
Translational Breast Cancer Research (2024) Vol. 5, pp. 20-20
Open Access | Times Cited: 1
Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO
Catherine M. Kelly, Kathleen Bennett, Caitriona Cahir, et al.
JCO Oncology Practice (2024)
Closed Access | Times Cited: 1
Catherine M. Kelly, Kathleen Bennett, Caitriona Cahir, et al.
JCO Oncology Practice (2024)
Closed Access | Times Cited: 1
In Silico Discovery of Multi-Target Natural Ligands and Efficient siRNA Design for Overcoming Drug Resistance in Breast Cancer via Local Therapy
Seyed Mohammad Javad Hashemi, Ali Barzegar, Javad Akhtari, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Seyed Mohammad Javad Hashemi, Ali Barzegar, Javad Akhtari, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana
James R. Wester, R. Wagner, Bosa Motladiile, et al.
JCO Global Oncology (2024), Iss. 10
Open Access
James R. Wester, R. Wagner, Bosa Motladiile, et al.
JCO Global Oncology (2024), Iss. 10
Open Access
Management of Early and LABC Breast Cancer: Chemotherapy and Targeted Therapy in Breast Cancer
Kanu Priya Bhatia, Sanal Fernandes, Akash Kumar
(2024), pp. 275-286
Closed Access
Kanu Priya Bhatia, Sanal Fernandes, Akash Kumar
(2024), pp. 275-286
Closed Access
Escalation of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer: to whom, when and why?
I. V. Kolyadina
Tumors of female reproductive system (2024) Vol. 20, Iss. 1, pp. 89-103
Open Access
I. V. Kolyadina
Tumors of female reproductive system (2024) Vol. 20, Iss. 1, pp. 89-103
Open Access
